ARL67156 trisodium hydrate

ARL67156 三钠水合物

ARL67156 trisodium hydrate

A658604-5mg

5mg

≥99%

-20°C储存,干燥

超低温冰袋运输

ARL67156 (FPL 67156) trisodium hydrate is a selective ecto-ATPase inhibitor. ARL67156 trisodium hydrate is a competitive inhibitor of NTPDase1 (CD39), NTPDase3 and NPP1, with K i s of 11, 18 and 12 μM, respectively. ARL67156 trisodium hydrate can be used Appearance:Solid IC50& Target:Ki: 11 μM (NTPDase1), 18 μM (NTPDase3), 12 μM (NPP1) In Vitro:ARL67156 trisodium hydrate (1-100 μM) potentiates neurogenic contractions in a concentration-dependent manner. ARL67156 trisodium hydrate (10 μg/mL, 24 h) increases the surface expression of CXCR3 on ATP-treated HMC-1 cells. ARL67156 trisodium h In Vivo:ARL67156 trisodium hydrate (1.1 μg/kg/day, administered with osmotic pumps implanted subcutaneously, for 28 days) prevents the development of calcific aortic valve disease in Warfarin (HY-B0687)-treated rats. ARL67156 trisodium hydrate (intraperitone Biological Activity:ARL67156 (FPL 67156) trisodium hydrate is a selective ecto-ATPase inhibitor. ARL67156 trisodium hydrate is a competitive inhibitor of NTPDase1 (CD39), NTPDase3 and NPP1, with K i s of 11, 18 and 12u2009μM, respectively. ARL67156 trisodium hydrate can be u

C15H23Br2N5Na3O13P3

834.61 g/mol

O[C@H]1[C@@H](O[C@H](COP(OP(C(Br)(Br)P(O)(O[Na])=O)(O[Na])=O)(O[Na])=O)[C@H]1O)N2C3=NC=NC(N(CC)CC)=C3N=C2.O.[2.75]